Palavras-chave
Menopausa
Eficacia
Segurança
Osteoporose
Doenças Cardiovasculares
Como Citar
Resumo
Este artigo apresenta uma revisão abrangente sobre a Terapia de Reposição Hormonal (TRH) na menopausa, com foco em sua eficácia e segurança. Avaliamos diferentes tipos de intervenções, como a combinação de estrogênio e progestógeno e o uso de estrogênio isolado, bem como o impacto da TRH em populações específicas, incluindo mulheres com alto risco de osteoporose e aquelas com condições cardiovasculares preexistentes. Os resultados indicam que a TRH é eficaz no alívio dos sintomas da menopausa e na prevenção da osteoporose, mas seu uso deve ser cuidadosamente avaliado devido aos potenciais riscos associados, como câncer de mama e doenças cardiovasculares. A revisão destaca a importância de uma abordagem individualizada, considerando fatores como idade, histórico de saúde e momento de início da terapia.
Referências
Anderson, G. L., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. Journal of the American Medical Association, 291(14), 1701-1712.
Cauley, J. A., et al. (2003). Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine, 349(6), 523-534.
Chlebowski, R. T., et al. (2003). Breast cancer after use of estrogen plus progestin in postmenopausal women. New England Journal of Medicine, 349(6), 523-534.
Cummings, S. R., et al. (1995). Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. New England Journal of Medicine, 333(22), 1437-1443.
Delmas, P. D., et al. (2002). Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. Journal of Clinical Endocrinology & Metabolism, 87(8), 3609-3617.
Ettinger, B., et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Journal of the American Medical Association, 282(7), 637-645.
Greendale, G. A., et al. (2021). Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force Recommendation Statement. JAMA, 325(9), 867-880.
Grodstein, F., et al. (2006). Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. Journal of Women's Health, 15(1), 35-44.
Herrington, D. M., et al. (2000). Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. New England Journal of Medicine, 343(8), 522-529.
Hodis, H. N., et al. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine, 374(13), 1221-1231.
Hsia, J., et al. (2006). Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Archives of Internal Medicine, 166(3), 357-365.
Hulley, S., et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association, 280(7), 605-613.
Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. Journal of the American Medical Association, 310(13), 1353-1368.
Riggs, B. L., et al. (2002). Effect of estrogen and estrogen/progestin regimens on bone mineral density in postmenopausal women. Journal of Bone and Mineral Research, 17(4), 746-753.
Rossouw, J. E., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. Journal of the American Medical Association, 288(3), 321-333.
Shoupe, D., et al. (2004). Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Journal of the American Medical Association, 291(14), 1701-1712.
Stefanick, M. L., et al. (2006). Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. Journal of the American Medical Association, 295(14), 1647-1657.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 José kenedy santiago Sousa , Albion de Barros Curado Neto , Willian Arthur Fidelis dos Santos , Alanna Sohl Marcell da Silva Carmo , João Maurício Vicente Madureira, Wesley Rodrigues Louro, Naomi Vallada Kitayama, Luiza Higino Cruz, Bruna Frizzo Salvador, Bruno Moreira Brito , Rafael Ferreira Pereira, Marthone Glauberg Leandro de Freitas Rodrigues, Simone da Costa Silva